Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes
    3 April 2025

    First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

    The United States Cystic Fibrosis Foundation released the first guideline on newborn screening for cystic fibrosis (CF), in order to improve timely detection of CF in infants from all racial and ethnic backgrounds. The new guideline, based on systematic literature reviews and published in the International Journal of Neonatal Screening, reflects rigorous scientific investigation and perspectives from parents, CF specialists, public health representatives, primary care providers and genetic counselors.

  • 3 April 2025
    OPRA Exam Results - Academically achieves monumental success in the first ever OPRA exam 2025!

    Academically is a leading healthcare edtech platform with global operations. It serves as a one-stop solution helping global healthcare professionals prepare for international licensure exams. With a proven success rate and an unbeatable track record, Academically continues to empower thousands of healthcare professionals in achieving their global career goals.

  • 27 March 2025
    How healthy microbes in infancy reduce diabetes risk
    Exposure to antibiotics during a key developmental window in infancy can stunt the growth of insulin-producing cells in the pancreas and may boost risk of diabetes later in life, new research in mice suggests. The study, published this month in the journal Science, also pinpoints specific microorganisms that may help those critical cells proliferate in early life.
  • 27 March 2025
    mRNA-based COVID-19 vaccines train the ‘long-term memory’ of the immune system
    Researchers at the University of Cologne have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential future infections / publication in Molecular Systems Biology
  • 27 March 2025
    Aspen Biopharma Labs gets warning letter from USFDA
    The U.S. Food and Drug Administration inspected Aspen Biopharma Labs Private Limited, drug facility; at Rangareddy region from September 16 to September 21, 2024. And they get a warning letter which summarizes significant deviations from Current Good Manufacturing Practice CGMP for active pharmaceutical ingredients.
  • 26 March 2025
    Growing Body of Evidence Links HPV with Heart Disease
    In addition to causing several types of cancer, human papillomavirus appears to bring a significantly increased risk of heart disease and coronary artery disease, according to a study being presented at the American College of Cardiology's Annual Scientific Session.
  • 26 March 2025
    New Evidence Links Microplastics with Chronic Disease

    Tiny fragments of plastic have become ubiquitous in our environment and our bodies. Higher exposure to these microplastics, which can be inadvertently consumed or inhaled, is associated with a heightened prevalence of chronic noncommunicable diseases, according to new research being presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

  • 26 March 2025
    Blujepa (gepotidacin) approved by USFDA for treatment of uncomplicated urinary tract infections
    Discovered by GSK scientists, Blujepa is a first-in-class oral antibiotic with a novel mechanism of action that is part of GSK’s infectious diseases portfolio.
  • 24 March 2025
    Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
    Innovent Biologics, Inc , a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354
  • 21 March 2025
    Novartis receives third FDA approval for oral Fabhalta® (iptacopan)
    Novartis announced that oral Fabhalta iptacopan has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition.
Subscribe to Pharma News